Last $221.78 USD
Change Today -0.59 / -0.26%
Volume 1.4M
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 3:28 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$222.66
Previous Close
$222.36
Day High
$222.79
Day Low
$220.45
52 Week High
01/26/15 - $228.43
52 Week Low
02/5/14 - $110.62
Market Cap
66.4B
Average Volume 10 Days
1.7M
EPS TTM
$5.34
Shares Outstanding
299.8M
EX-Date
11/18/14
P/E TM
41.5x
Dividend
$0.20
Dividend Yield
0.09%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,500 Employees
Last Reported Date: 11/5/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Non-Executive Officer
Total Annual Compensation: $641.5K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Litigation against Allergan Inc

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announced that class action litigation has been brought on behalf of those who sold the common stock of Allergan Inc. between February 25, 2014 and April 21, 2014, inclusive. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. The complaint alleges that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan. Pershing Square then allegedly traded on this material, non-public information by purchasing an approximately 9.7% stake in Allergan during the Class Period, without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium.

The Shareholders Foundation, Inc. Files Lawsuit against Allergan, Inc

The Shareholders Foundation Inc. announced that a lawsuit was filed on behalf of investors who SOLD shares of Allergan Inc. between February 25, 2014 and April 21, 2014, over alleged Violations of Federal Securities Laws Violations by Pershing Square Capital Management, L.P, William A. Ackman, and Valeant Pharmaceuticals International Inc. The plaintiff claims that by purchasing Allergan Inc. stock with material, non-public information between February 25, 2014 and April 21, 2014, and by communicating material, non-public information, defendants violated the Securities Exchange Act of 1934.

Allergan Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 through Jan-11-2015

Allergan Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 through Jan-11-2015. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Presentation Date & Speakers: Jan-10-2015, David E. I. Pyott, Chairman and Chief Executive Officer. Jan-11-2015, David E. I. Pyott, Chairman and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $221.78 USD -0.59

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $273.27 USD -0.61
Astellas Pharma Inc ¥1,823 JPY +14.00
Medtronic PLC $72.99 USD -0.42
Regeneron Pharmaceuticals Inc $414.04 USD +6.04
Shire PLC 4,898 GBp +18.00
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 51.8x
Price/Sales 9.4x
Price/Book 9.3x
Price/Cash Flow 46.9x
TEV/Sales 8.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.